Background: Childhood cancer survivors are at increased risk for pulmonary morbidity and mortality. International guidelines recommend pulmonary function tests (PFT) during follow-up care.
INTRODUCTION
Every fifth childhood cancer survivor (CCS) is exposed to pulmotoxic cancer treatment with either bleomycin, busulfan, nitrosoureas, and/or Abbreviations: CCS, childhood cancer survivors; CI, confidence interval; CNS, central nervous system; CuI, cumulative incidence; DLCO, diffusion capacity of the lung for carbon monoxide; Gy, gray; HSCT, hematopoietic stem cell transplantation; ICCC-3, International Classification of Childhood Cancer, Third edition; IQR, interquartile range; MBW, multiple breath washout; OR, odds ratio; PFT, pulmonary function tests; SCCR, Swiss Childhood Cancer Registry radiotherapy involving lung tissue. 1 These treatments can lead to lung damage and pulmonary diseases that are a major cause of mortality and morbidity in CCS. CCS have a threefold increased risk of hospitalization due to pulmonary diseases and up to 14 times increased risk of late pulmonary death. [2] [3] [4] In Switzerland, 12% of CCS report one or more pulmonary diseases, possibly caused by cancer treatment. 1 In the St. Jude Lifetime Cohort, in which all CCS received risk-based screening at a median of 25 years after cancer treatment, 65% of 417 CCS exposed to pulmotoxic treatment had abnormal pulmonary function tests (PFT). 5 Prior to testing, more than half were unaware of their pulmonary dysfunction, which was the most frequently detected adverse health effect. 5 A similar study performed in 370 CCS from the City of Hope Hospital also found that the yield of screening for pulmonary dysfunction was higher (84%) than for other late effects including hearing loss (23%), low bone mineral density (23%), or hypothyroidism (11%). 6 Early detection of pulmonary dysfunction can help guide treatment and inform lifestyle modifications to mitigate progression and reduce exacerbation. 7 Since 1995 international follow-up care guidelines in the United Kingdom and since 2003 in the United States have therefore recommended PFT for CCS at risk of pulmonary dysfunction. 8, 9 Switzerland has no national guidelines, and routine practice of PFT in follow-up care after childhood cancer is unknown.
In this national, population-based study we retrospectively studied three aspects of pulmonary function testing during follow-up care of CCS in Switzerland: the type of PFT performed, how many CCS were tested, and the characteristics of CCS who had had PFT compared to those who had not.
METHODS

Study population
This study is a nested cohort in the Swiss Childhood Cancer Registry (SCCR). The SCCR includes all children and adolescents who live in Switzerland and are diagnosed with leukemia, lymphoma, central nervous system (CNS) tumors, malignant solid tumors, or Langerhans cell histiocytosis prior to the age of 21 years. 10 The SCCR is a national, population-based registry that includes more than 95% of childhood cancer patients diagnosed since 1995. 11 It registers information on cancer diagnosis and treatment, and personal information. Tumors are classified according to the International Classification of Childhood Cancer, third edition (ICCC-3). 12 Ethics approval was granted by the Ethics Committee of the Canton of Bern to the SCCR (KEK-BE: 166/2014).
Inclusion criteria
We included all CCS registered in the SCCR who were treated with pulmotoxic chemotherapy and/or chest radiotherapy in a Swiss pediatric oncology center up to the age of 16 years and aged ≥6 years at time of the study ( Supplementary Fig. S1 ). We defined pulmotoxic chemotherapy as treatment with busulfan, bleomycin, and/or nitrosoureas (lomustine, carmustine) according to international follow-up care guidelines (Supplementary Table S1 ). 8, 9 Radiotherapy relevant for this study was defined as any radiation applied to the whole body, mantle-field, chest, lungs, mediastinum, or thoracic spine. 8, 9 We included CCS diagnosed from 1990 to 2013. According to Swiss law, medical records need to be stored for only 10-20 years so we excluded those CCS diagnosed before 1990 to preserve completeness of data. 13 We excluded CCS diagnosed after 2013 because treatment was not always completed when data collection started in 2016.
Medical records review
For this retrospective data collection, we accessed medical records in 2016 in all Swiss pediatric oncology centers and the corresponding pediatric respiratory clinics. We collected PFT, reports of pediatric pulmonologists, reports of ambulatory oncology care, hospitalization discharge reports, and cancer treatment protocols.
Switzerland has no national recommendations on type and timing of PFT in CCS after pulmotoxic treatment. We therefore decided on a simplified approach and collected all PFT performed in the first 5 years after pulmotoxic treatment regardless of the reasons for performing the tests. We collected information on all tests specifically recommended for assessment of pulmonary late effects by international guidelines, that is, spirometry, plethysmography, and diffusion capacity of carbon monoxide (DLCO), 8, 9 and also noted other tests performed including bronchodilator tests, cardiopulmonary exercise tests, measurement of exhaled nitric oxide, bronchial challenge test, and multiple breath inert gas washout. We reviewed medical reports from pulmonologists and pediatric oncology for pulmonary diagnoses, distinguishing between noninfectious pulmonary diseases and pulmonary infections. Noninfectious pulmonary diseases found in the medical records were asthma, diffuse parenchymal lung disease (restrictive lung disease, interstitial lung disease, bronchiolitis obliterans), atelectasis, chest wall deformity, emphysema, and acute respiratory distress syndrome (ARDS). Infections listed in the records were viral or bacterial pneumonia and aspergillosis. CCS who had both noninfectious pulmonary disease and infection, were classified as having noninfectious pulmonary disease, which we considered more permanent.
We collected detailed information on cancer treatment from the SCCR or, when it was not available in the SCCR, medical records, recording the start date of pulmotoxic treatment. We classified CCS into three groups depending on the pulmotoxic treatment: chest radiotherapy, pulmotoxic chemotherapy, or both. We determined whether CCS were registered clinical study participants, were treated according to a clinical study protocol but not registered, or were not treated according to a clinical study protocol. If children received multiple pulmotoxic treatments (e.g., for primary tumor and relapse) the last treatment was the one used in categorization of clinical study participation. We recorded information on thoracic surgery with thoracotomy or thoracoscopy for tumor/metastasis resection (wedge, lobe, whole lung), rib resection, laminectomy, bone biopsy, en bloc resection of rib, lung tissue, and/or diaphragm. We recorded autologous or allogeneic hematopoietic stem cell transplantation (HSCT). We also collected information on relapse of the cancer and survival.
Statistical analysis
We assessed the proportion of CCS who had different types of PFT during the first 5 years after pulmotoxic treatment. Among those who had been tested, we calculated the median number, interquartile range, and range of PFT. We stratified the results by sex, age at diagnosis, diagnosis, period of cancer diagnosis, pulmotoxic treatment, thoracic surgery, HSCT, clinical study participation, pulmonary disease diagnosis, or death during follow-up care and assessed associations using univariable and multivariable logistic regression models. In a sensitivity analysis we excluded all children with asthma (19 children) from the model, because we suspected that children with asthma would receive PFT to assess asthma control rather than screen for sequelae of cancer treatment. Finally, we used the Kaplan-Meier method to estimate cumulative incidence curves for PFT performed during the first 5 years after pulmotoxic treatment overall, and stratified by period of cancer diagnosis. CCS who had not had a PFT were censored at 5 years of follow-up, death, or start of data collection (February 2, 2016), whichever occurred first. In eight cases in which we had no information on the start of pulmotoxic treatment, we considered the start date to be the date of the cancer diagnosis.
We used Stata (Version 14, Stata Corporation, Austin, TX) for all analyses.
RESULTS
Characteristics of study population
Of 2989 eligible CCS, 419 (14%) received pulmotoxic treatment and were at least 6 years old at start of data collection. Medical records were unavailable in 47 of those CCS (Supplementary Fig. S1 ). Table 1 lists the characteristics of the 372 CCS included in the analysis, 147 of whom had received pulmotoxic chemotherapy (40%), while 324 received chest radiotherapy (87%).
Pulmonary diseases were present in 72 CCS, of whom 47 had noninfectious pulmonary disease and 25 pulmonary infections (Supplementary Table S2 ). Cardiopulmonary exercise test 11
Pulmonary function tests
Multiple breath inert gas washout 2 (1)
IQR, interquartile range. a Column percentages are given.
tested child was 3 (IQR 2-4). Other tests performed were bronchodilator tests, cardiopulmonary exercise tests, fractionated exhaled nitric oxide, bronchial challenge tests, and multiple breath inert gas washout (Table 2 ).
Predictors for pulmonary function tests
Testing varied strongly by cancer treatment centers: center A was clearly above average and had done both plethysmography and/or spirometry and DLCO in 79% of children. All other centers did plethysmography and/or spirometry in 26-58%, and DLCO in 3-44%
( Figure 1 , Supplementary Table S3) . Children who were older at diagnosis were more often tested (had higher odds for being tested)
than those younger at diagnosis, although age at diagnosis was not statistically significant after adjustment ( F I G U R E 1 Proportion and 95% confidence intervals of survivors exposed to pulmotoxic treatment with pulmonary function tests by Swiss pediatric oncology center (SPOG) We observed no differences by gender, period of cancer diagnosis, pulmotoxic treatments, thoracic surgery, and HSCT (Table 3 ). In a sensitivity analysis in which we excluded all patients with asthma, results
were essentially the same.
Cumulative incidence of pulmonary function tests
The cumulative incidence of children who had a PFT was 31% 1 year after pulmotoxic treatment, 44% after 2 years, 48% after 3 years, 51% after 4 years, and 52% after 5 years. Cumulative incidence did not differ between periods of cancer diagnosis (Figure 2 ).
DISCUSSION
In our nationwide study of all children who were diagnosed with cancer and exposed to pulmotoxic treatment in Switzerland between 1990
and 2013, we found that only half had PFT during follow-up care. This contrasts sharply with international recommendations (Supplementary Table S1 ). 8, 9 Only 50% of children had a plethysmography and/or spirometry, and only 33% a DLCO. This did not depend on type of pulmotoxic treatment, but varied significantly between treatment centers and test, from 3% to 79%. Lymphoma survivors and those diagnosed with a noninfectious pulmonary disease were most likely to be tested, while CNS tumor survivors and those not treated according to a study protocol were least likely tested. Most children had the first test within 2 years after pulmotoxic treatment.
Guidelines for PFT in follow-up care differ for type of test and timing. US follow-up care guidelines recommend performing a PFT at entry into long-term follow-up which is defined as "two or more years after completion of therapy" in children exposed to pulmotoxic chemotherapy and/or chest radiotherapy, and thereafter as clinically indicated. 9 They recommend performing a spirometry and a DLCO. UK follow-up care guidelines recommend PFT in exposed children at the end of treatment without further specifying the type of test. In children with symptoms or an abnormal first PFT, the test should be repeated after 1 year. 8 In single centers like St. Jude Children's Research Hospital and City of Hope in the United States, follow-up care guidelines are implemented among CCS enrolled in lifetime cohorts or long-term followup clinics. 5, 6 For the St. Jude lifetime cohort, 2843 (60%) of survivors participated in long-term follow-up. Among those, all 10-year survivors with pulmotoxic exposure (n = 417, 100%) were screened according to their follow-up guidelines. 5 However, no previous study has investigated PFT in follow-up care on a national level, and in our study we found that only 50% of the children had had PFT. We have reports from single centers in Europe as well, where pulmonary function outcomes in CCS have been studied retrospectively. In a Dutch study, 193
of the 220 (88%) CCS exposed to pulmotoxic treatment had a PFT.
This is more than in Switzerland, but less than optimal, considering that the center observes follow-up care guidelines from the United
States. 14 In an Israeli study of 170 survivors of HSCT, only 34% had had PFT according to their hospital internal protocol. 15 This study cannot be compared directly to ours as the Israeli protocol was stricter and required more tests, including PFT before HSCT, and at 3, 6, and 12 months post-HSCT. No study has investigated in detail which PFT were done in children exposed to pulmotoxic treatments. In our study, DLCO was measured in only 33% of children, which is surprising, since it is a sensitive measure for detecting mild or preclinical interstitial lung disease and helps distinguish interstitial lung disease from extrapulmonary causes of restriction. 16 Moreover, it is noninvasive, cheap, and needs little time. Also, multiple breath inert gas washout, which measures lung clearance index, was rarely used, although it is sensitive for detection of early small airway disease. Four of the eight pediatric cancer treatment centers had the setup to perform such measurements by 2016 and obviously did not use it for screening of CCS, but mainly for patients with other lung diseases such as cystic fibrosis and for research rather than clinical purposes. 17, 18 The most important predictor for pulmonary function testing was the treatment center, with proportions varying from 24% to 79% for plethysmography and/or spirometry and 3% to 79% for DLCO. This did not depend on the size of the center. We observed the highest proportion in a smaller center with only 28 exposed CCS. This center always performed DLCO together with plethysmography and/or spirometry in CCS. All other centers tested DLCO only in some of the children who had spirometry and/or plethysmography; in three cen- Table S5 ). The existing follow-up care guidelines all recommend follow-up care for nitrosoureas, but disagree on craniospinal radiotherapy: UK guidelines recommend PFT, while US guidelines do not. 8, 9 When we excluded CCS with craniospinal irradiation from the regression, we found that CNS tumor survivors still had less PFTs compared to leukemia survivors. An explanation might be that survivors of CNS tumors often have multiple morbidities, which can shift the attention of clinicians away from the lung. 19 Clinicians might have skipped PFT because they thought that other tests might be more important, or the children were regarded as unable to perform PFT.
Children treated for lymphomas were tested most often. Lymphomas have the best survival rates among all childhood cancers. 20 Late effects after lymphoma are well studied and physicians' awareness for pulmonary late effects is clearly highest. 21, 22 This might also have been influenced by the historically more extensive radiation fields involving parts of the lungs with a clear association to pulmonary dysfunction. 22 Children who were not treated according to a study protocol had less PFT. Children cannot be treated according to a protocol when there is no study protocol for their specific disease, or they fail to meet inclusion criteria of existing protocols. Table   S1 ). In our study, the proportion of children tested did not depend on the type of pulmotoxic treatment the children had received. Even We did not investigate whether a first PFT was performed later than 5 years after diagnosis as long-term follow-up guidelines recommend the initiation either at the end of cancer treatment (United Kingdom), 8 or 2 or more years after completion of therapy (United States). 9 However, our study is likely to have overestimated the adherence to guidelines because we had no detailed information on the indication for PFT. We hypothesized that PFTs are done often because survivors have symptoms or already diagnosed pulmonary disease rather than because physicians follow international monitoring recommendations on riskbased screening. We used presence of pulmonary disease as surrogate for symptoms or diagnosed pulmonary disease before testing. Our analysis supported our initial hypothesis and found that having a symptomatic pulmonary disease is the strongest predictor for having PFTs during follow-up care.
Some guidelines and study protocols recommend imaging such as chest x-ray or computer tomography, but we did not collect this information, because in some clinics access to radiology departments was difficult. Finally, for some participants chemotherapy doses could not be found because in certain older records not all treatment information was available. In such cases we could only confirm whether CCS had chemotherapy.
The strengths of our study include the nationwide, populationbased setting. We had original information from medical records to investigate lung health monitoring; we were able to include CCS with different childhood cancer diagnoses and different treatment proto- We observed further that existing guidelines are inconsistent. 8, 9 Physician compliance might improve were guidelines harmonized.
The need for standardized guidelines for follow-up care was recognized by oncologists and general practitioners in adult and pediatric care in a recent study among Swiss physicians. 23 The International
Late Effects of Childhood Cancer Guideline Harmonization Group (www.ighg.org) is currently developing recommendations for pulmonary disease surveillance after cancer treatment to harmonize existing recommendations. 24 The new guidelines, based on current literature, existing guidelines, and broad expert consensus, will propose recommendations about who needs monitoring at what frequency, for how long, and the modalities that should be used (e.g., which PFT, or imaging). Upon publication, these guidelines should be adapted to local needs of different countries and then implemented to offer high-quality follow-up care to all former cancer patients. 
AUTHOR CONTRIBUTIONS
Conceptualization
